Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

PARP Inhibitors Intriguing Despite Research Setbacks

April 26th 2012

Despite initial disappointing findings on overall survival, PARP inhibitors remains under active investigation for patients with ovarian cancer.

Supreme Court Asks for Reconsideration on BRCA1 and BRCA2 Patents

March 27th 2012

The US Supreme Court has asked an appellate court to reconsider its decision regarding patents held on two genes.

Improved Survival in Women With Invasive Epithelial Ovarian Cancer and Germline BRCA Gene Mutations

March 26th 2012

Researchers are reporting better survival rates in women with invasive EOC and germline mutations in the tumor suppressor genes BRCA1 and BRCA2 than in patients who are noncarriers.

Dr. Birrer on the Ovarian Cancer Avastin OS Benefit

March 2nd 2012

Dr. Michael Birrer from Massachusetts General Hospital Cancer Center on the Ovarian Cancer Avastin OS Benefit

Benefits of Bevacizumab in Ovarian Cancer Clarified

March 1st 2012

Bevacizumab has failed to demonstrate statistically significant improvements in OS for women with recurrent ovarian cancer in 2 recent clinical trials.

Bevacizumab Delivers Ovarian Cancer Benefit But Not OS Upgrade

February 22nd 2012

Bevacizumab improved progression-free survival in patients with ovarian cancer but was not shown to affect overall survival.

Dr. Birrer Discusses the GOG0218 and ICON7 Trials

February 2nd 2012

Dr. Michael Birrer, from Massachusetts General Hospital Cancer Center, Discusses the GOG0218 and ICON7 Trials

BRCA1 and BRCA2 Mutations Yield Better Prognosis in Ovarian Cancer Patients

January 25th 2012

Patients with ovarian cancer who express BRCA1/2 mutations demonstrated a better overall survival after 5 years.

Dr. Birrer Discusses Recurrent Ovarian Cancer Treatment

January 23rd 2012

Dr. Michael Birrer, from Massaschusetts General Hospital Cancer Center, Discusses Recurrent Ovarian Cancer Treatment

Brain Metastasis Common in Ovarian Cancer

January 20th 2012

Half of all women with advanced ovarian cancer who develop brain cancer have a single metastasis to the brain.

Fertility Treatment Increases Risk of Ovarian Cancer

January 16th 2012

Subfertile women who undergo ovarian stimulation for in vitro fertilization have an increased risk of ovarian malignancies.

Avastin Increases PFS in Patients With Ovarian Cancer

December 29th 2011

Bevacizumab (Avastin) improved progression-free survival (PFS) in patients with ovarian cancer but was not shown to affect overall survival (OS), according to a new study...

Guidelines for Genetic Counseling or BRCA 1/2 Testing Are Often Ignored

October 25th 2011

Primary care physicians in the US adhere poorly to established guidelines for genetic counseling and testing for women who are at high risk of breast and ovarian cancer.

5 Abstracts Among SGO Highlights

September 30th 2011

This report highlights 5 abstracts relevant to the current and future management of patients with female pelvic malignancies.

ASCO 2011: What Nurses Need to Know

August 26th 2011

Personal perspectives from oncology nurses of abstracts presented at ASCO on research with the potential to change practice, important studies that failed to meet expectations, and topics particularly relevant to oncology nurses.

Bevacizumab Plus Chemotherapy May Improve Overall Survival In High-Risk Ovarian Cancer

August 2nd 2011

Concurrent and continued bevacizumab added to standard chemotherapy with carboplatin/ paclitaxel improved OS in women with high-risk ovarian cancer, according to an interim survival analysis of the ICON7 trial.

Judge Rules BRCA Genes Can Be Patented, Overturning Previous Decision

August 1st 2011

On July, 29, 2011, a US appeals court sided with Myriad Genetics, Inc's patents on the BRCA1 and BRCA2 genes.

Novel Agent Demonstrates Activity in Heavily Pretreated Ovarian Cancer That Progressed on Pegylated Doxorubicin

August 1st 2011

A novel topoisomerase-I inhibitor designated NKTR-102 demonstrated clinically significant activity as a single agent in patients with heavily pretreated ovarian cancer who failed prior PLD.

Bevacizumab Added to Chemotherapy Provides Meaningful Benefit in Recurrent Ovarian Cancer

July 27th 2011

Women with recurrent platinum-sensitive ovarian cancer had a 50% improvement in PFS when bevacizumab was added to chemotherapy and continued as maintenance therapy.

Dr. Vogelzang Discusses the Cabozantinib Trial Design

July 20th 2011

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses the Cabozantinib Trial Design